

Tin-based antitumour drugs¹

Marcel Gielen

*Department of General and Organic Chemistry, Faculty of Applied Sciences, Free University of Brussels,
Room 8G512, Pleinlaan 2, B-1050 Brussels, Belgium*

Contents

Abstract	41
1. Introduction	41
2. Early studies on diorganotin pyridinedicarboxylates	42
3. Substituted bis(salicylato)tetraorganodistannoxanes	43
4. Substituted di- <i>n</i> -butyltin dibenzoates	43
5. Di- <i>n</i> -butyltin derivatives of mono-, di-, tri-, tetra- and perfluorobenzoic acids	43
6. Substituted triphenyltin benzoates	45
7. Substituted tri- <i>n</i> -butyltin benzoates	47
8. In vivo antitumour activities of organotin compounds	47
9. Conclusions	48
Acknowledgements	49
References	50

Abstract

An overview is given of the results of the in vitro screening against MCF-7, a mammary tumour, and WiDr, a colon carcinoma, of several series of organotin compounds synthesized in the Free University of Brussels. Many di- and triorganotin compounds exhibit very promising in vitro antitumour activities. Di-*n*-butyltin bis(2,5-dihydroxybenzoate) is as active as cisplatin in vivo against murine Colon 26 carcinoma.

Keywords: Antitumour drug; Carcinoma; Organotin compound; Tin compound

1. Introduction

Cisplatin is unfortunately very nephrotoxic but is effective against testicular carcinomas, which had almost invariably caused death before cisplatin was discovered

¹ Keynote lecture presented at the Third International Symposium on Applied Bioinorganic Chemistry (ISABC-3), Fremantle, Perth, Western Australia, 11–15 December 1994.

but have become curable nowadays thanks to its use. However, cisplatin does not show any, or only little, effect on more common tumours such as lung tumours or gastrointestinal adenotumours. The excellent activity of cisplatin against testicular carcinomas shows that it should be possible to find new metal-based drugs capable of curing specific types of tumours.

This has been a considerable impetus for inorganic and organometallic chemists to search for new metal compounds with similar good activities, preferably against tumour types that are responsible for the major share of cancer mortality today.

2. Early studies on diorganotin pyridinedicarboxylates

We have synthesized several series of organotin compounds that exhibit interesting *in vitro* antitumour activities [1–3]. For instance, di-*n*-butyltin, di-*t*-butyltin and diphenyltin 2,6-pyridinedicarboxylates [4,5] were found to be more active than cisplatin against MCF-7, a mammary tumour, and WiDr, a colon carcinoma.

Because Crowe has proposed that, among the factors responsible for the mode of action of diorganotin compounds R_2SnX_2 , the organic groups R determine the potential activity [6], we prepared some more diorganotin 2,6-pyridinedicarboxylates $C_5H_3N(COO)_2SnRR'$ by varying the groups R and R' bound to tin and found that almost all the compounds synthesized were less active than the di-*n*-butyltin derivative (Table 1) [7].

The structure of one of these compounds, bis[aquaethyl(phenyl)(2,6-pyridinedicarboxylato)tin(IV)] [8(a)], is shown in Fig. 1.

Table 1

ID_{50} values of selected 2,6-pyridinedicarboxylatodiorganotin(IV) derivatives $C_5H_3N(COO)_2SnRR'(H_2O)$ against MCF-7 and WiDr

RR'	ID_{50} (ng ml ⁻¹) against	
	MCF-7	WiDr
<i>n</i> -Bu ₂	60	106
(<i>p</i> -MeO-Ph) ₂	4930	15800
Ph ₂	170	372
PhMe	2187	3283
PhEt	918	4046
Ph ⁿ Pr	223	1094
Ph ⁱ Pr	402	1169
Ph ⁿ Bu	761	3705
Ph ⁱ Bu	121	831
Ph(PhCH ₂)	2910	10995
Ph(ⁱ BuCH ₂ CH ₂)	50	161
Ph(PhMe ₂ CCH ₂)	40	106




Fig. 1. Molecular structure of bis[aquaethyl(phenyl)(2,6-pyridinedicarboxylato)tin(IV)] [8(a)].

3. Substituted bis(salicylato)tetraorganodistannoxanes

A series of 1:1 condensation compounds of substituted salicylic acids with diorganotin oxides was synthesized (see Fig. 2 [8(b)]). They were tested against the same two human tumour cell lines. Typical ID_{50} values obtained are 50 ng ml^{-1} against MCF-7 and 300 ng ml^{-1} against WiDr [2,3] (Table 2). The 5-methoxysalicylate was one of the most active compounds of this series.

Several 1:1 condensation compounds of substituted salicylic acids with diorganotin oxides having various organic groups R linked to tin were also synthesized. Again all compounds prepared were less active than the corresponding di-*n*-butyltin ones [2,3] (Table 3).

4. Substituted di-*n*-butyltin dibenzoates

Di-*n*-butyltin dibenzoates, including some disalicylates (where X means 2-OH), were prepared from diorganotin oxides and carboxylic acids in a 1:2 molar ratio [2,3] (Fig. 3).

The 4-hydroxy-3-methoxybenzoate exhibits quite high in vitro activities (Table 4).

5. Di-*n*-butyltin derivatives of mono-, di-, tri-, tetra- and perfluorobenzoic acids

Several 1:1 and 1:2 condensation compounds of di-*n*-butyltin oxide with mono- [10], di- [11], tri-, tetra- [12] and pentafluorobenzoic [13] acids were prepared recently (Fig. 4).

Table 2

ID₅₀ values of di-*n*-butyltin(IV) derivatives of substituted salicylic acids {[YC₆H₃(OH)COOSnBu₂]₂O}₂, and of cisplatin and mitomycin C against MCF-7 and WiDr

Y	ID ₅₀ (ng ml ⁻¹) against	
	MCF-7	WiDr
3-CH ₃	44	330
4-CH ₃	51	316
5-CH ₃	90	337
3-CH ₃ O	45	323
4-CH ₃ O	190	1794
5-CH₃O	29	122
4-NH ₂	42	330
5-NH ₂	38	316
5-COOH	41	190
5-F	46	256
5-Cl	31	280
5-SO ₃ H	47	107
Cisplatin	850	624
Mitomycin C	3	17

Table 3

ID₅₀ values of selected 1:1 condensation compounds of diorganotin(IV) oxides with 5-methoxysalicylic acid against MCF-7 and WiDr

RR'	ID ₅₀ (ng ml ⁻¹) against	
	MCF-7	WiDr
ⁿ Bu ₂	29	122
Me ⁿ Bu	1488	2784
Et ₂	2236	4806
ⁿ Oct ₂	4677	10639

They do exhibit very promising in vitro antitumour activities (Table 5).

Against MCF-7 the difluorobenzoates are more active than the monofluorobenzoates, which shows that the activity is enhanced when the number of fluorine atoms on the benzoate moiety is increased. They indeed provide ID₅₀ values comparable with that of mitomycin C. The ID₅₀ value of the corresponding 2,3,6-trifluorobenzoate is of the same order of magnitude, while those of the 2,3,4,5-tetra- and pentafluorobenzoates are lower. Against WiDr all fluorobenzoates exhibit comparable activities, except the 2,3-difluoro compound which is slightly more active.




Fig. 2. X-Ray crystal structure of the bis(3,4,5-trimethoxysalicylato)tetra-*n*-butyl-distannoxane dimer [8(b)].

6. Substituted triphenyltin benzoates

Substituted triphenyltin benzoates [14,15] have been found to be very active *in vitro* against the same two human tumour cell lines (Table 6).


Fig. 3. X-Ray crystal structure of di-*n*-butyltin 5-chlorosalicylate [9].

Table 4

ID₅₀ values of a series of diorganotin(IV) dicarboxylates (X, Y, Z-C₆H₂COO)₂SnⁿBu₂ and of cisplatin against MCF-7 and WiDr

X	Y	Z	ID ₅₀ (ng ml ⁻¹) against	
			MCF-7	WiDr
H	H	2-F	74	242
H	H	3-F	63	197
H	H	4-F	90	309
2-OH	H	H	541	2974
2-OH	H	3-OCH ₃	105	474
2-OH	H	5-OCH ₃	54	611
2-OH	H	5-Cl	89	319
4-OH	H	3-OCH₃	44	82
3-OCH ₃	4-OCH ₃	5-OCH ₃	84	356
2-OCH ₃	3-OCH ₃	4-OCH ₃	93	398
2-OCH ₃	4-OCH ₃	5-OCH ₃	132	368
Cisplatin			850	624

Table 5

ID₅₀ values of compounds of the type $\{[(F_nC_6H_{5-n}COO)(n-C_4H_9)_2Sn]_2O\}_2$ (1:1 molar ratio) and of reference compounds tested against two human tumour cell lines, MCF-7 and WiDr

Substituent	ID ₅₀ (ng ml ⁻¹) against	
	MCF-7	WiDr
2-F	91	330
4-F	81	360
2,3-F ₂	9	120
2,5-F ₂	7	277
2,6-F ₂	3	174
3,5-F ₂	11	172
2,3,6-F ₃	13	200
2,3,4,5-F ₄	35	250
F ₅	44	214
Cisplatin	850	624
Mitomycin C	3	17

7. Substituted tri-*n*-butyltin benzoates

Tri-*n*-butyltin difluorobenzoates [16] (see Table 7) are less active than the corresponding triphenyltin derivatives and also less active than the corresponding di-*n*-butyl compounds [11].

8. In vivo antitumour activities of organotin compounds

The antitumour activity in tumour-bearing mice was screened for four triorganotin compounds, namely triphenyltin 5-sulphosalicylate (TPSS), triphenyltin 5-aminosalicylate (TPAS), triphenyltin 4-fluorobenzoate (TPFB) and tri-*n*-butyltin 2,6-difluorobenzoate (TBDFB), and for a diorganotin compound, di-*n*-butyltin bis(2,5-dihydroxybenzoate) (DBDHB). The results [17] are presented in Table 8.

The T/C (>0.6) and GDF (<1) data of TPSS, TPAS, TPFB and TBDFB show that a single dose administration of these compounds was inactive against the tumour Colon 26 in mice. DBDHB showed the largest antitumour activity. For DBDHB the measured T/C of 0.43 was about 1.5–2 times lower than for the other compounds tested. Also, the GDF > 1, above the cut-off level for sensitivity, indicated that DBDHB exerted marked antitumour activity. The treatment with TPSS, TPAS, TPFB and TBDFB resulted in a slight increase in medium life span (MLS) (111%). Furthermore, all treated mice showed a large weight loss (MWL), most for DBDHB with an MWL of 18.7% at day 4. Part of the weight loss was due to cachexia caused by the tumour.

To compare the results of the organotin derivatives with other metal-based drugs, the results of a single dose administration of cisplatin (5.5 and 9 mg kg⁻¹) are also




Fig. 4. X-Ray crystal structure of the bis(perfluorobenzoato)tetra-*n*-butyl-distannoxane dimer [13].

depicted in Table 8. The treatment with cisplatin at a dose of 5.5 mg kg^{-1} resulted in the same T/C (0.73) as for TPSS, TPAS, TPFB and TBDFB. In the experiment with DBDHB it was attempted to give the drug again after an interval of 1 week. However, the toxicity was considered too severe to continue treatment.

9. Conclusions

To summarize, we can state that several organotin compounds exhibit rather promising *in vitro* antitumour activities [18] against human tumour cell lines. However, more work has to be done on the preparation and testing of organotin molecules that might become useful antitumour drugs in the future.

Table 6

Inhibition doses ID_{50} against two human tumour cell lines, MCF-7 and WiDr, obtained for a series of substituted triphenyltin benzoates and for a clinically used antitumour drug, cisplatin

Compound	ID_{50} (ng ml ⁻¹) against	
	MCF-7	WiDr
2-CH ₃ O-C ₆ H ₄ CO ₂ SnPh ₃	16	15
4-F-C ₆ H ₄ CO ₂ SnPh ₃	15	14
2,3-F ₂ C ₆ H ₃ CO ₂ SnPh ₃	17	24
3,5-F ₂ C ₆ H ₃ CO ₂ SnPh ₃	18	17
2,4,5-(CH ₃ O) ₃ C ₆ H ₂ CO ₂ SnPh ₃	16	15
2-OH-5-Cl-C ₆ H ₃ CO ₂ SnPh ₃	11	18
2-OH-5-NH ₂ -C ₆ H ₃ CO ₂ SnPh ₃	14	17
2-OH-5-OCH ₃ -C ₆ H ₃ CO ₂ SnPh ₃	6	15
2-OH-5-SO ₃ H-C ₆ H ₃ CO ₂ SnPh ₃	100	131
2-OH ₃ -CH(CH ₃) ₂ -5-CH(CH ₃) ₂ -C ₆ H ₃ CO ₂ SnPh ₃	8	13
Cisplatin	850	624

Table 7

Inhibition doses ID_{50} obtained in vitro against six human tumour cell lines, MCF-7 and EVSAT (breast cancers), WiDr (a colon carcinoma), IGROV (an ovarian cancer), M19 (a melanoma) and A498 (a renal cancer), for two tri-*n*-butyltin difluorobenzoates and for three clinically used antitumour drugs

Compound	MCF-7	EVSAT	WiDr	IGROV	M19	A498
2,5-F ₂ C ₆ H ₃ COOSnBu ₃	38	12	58	20	58	80
2,6-F ₂ C ₆ H ₃ COOSnBu ₃	480	250	800	610	710	1100
Cisplatin	800	1200	650	79	520	1200
Carboplatin	5500	1100	1500	780	5300	3500
Doxorubicin	8	6	20	28	5	5

Acknowledgements

I would like to thank all my coworkers who prepared, purified and characterized the compounds reported in this paper and also especially Professor Dr. R. Willem, Dr. M. Biesemans and Dr. A. Delmotte who supervised this work. I also thank Mrs. I. Verbruggen for the acquisition of the NMR data and Dr. B. Mahieu for the acquisition of the Mössbauer spectra that were not discussed in this paper but that are essential for the characterization of the compounds. I am also indebted to Dr. D. de Vos, Mr. H.J. Kolker, Dr. J. Verweij, Professor Dr. G. Stoter, Dr. J.H.M. Schellens, Dr. C.M. Kuiper, Dr. G. Veerman and Professor Dr. G.J. Peters for the in vitro and in vivo tests. This research was supported by the Belgian National Fonds voor Wetenschappelijk Onderzoek (NFWO; Grant S2/5 CD F198, MG) and the Human Capital and Mobility Programme of the European Community (Contract ERBCHRXCT920016).

Table 8

Antitumour activity and toxicity of triphenyltin 5-sulphosalicylate (TPSS), triphenyltin 5-aminosalicylate (TPAS), triphenyltin 4-fluorobenzoate (TPFB), tri-*n*-butyltin 2,6-difluorobenzoate (TBDFB) and di-*n*-butyltin bis(2,5-dihydroxybenzoate) (DBDHB) on Colon 26-bearing mice

Treatment	GDF	maximum T/C (% (days))	Mean TD	ILS (%)	MWL (% (days))
Control			3.1 ± 1.2	100	11.2 (7)
TPSS, 5 mg kg ⁻¹	0.43	80 (3)	4.4 ± 1.5	111	14.7 (7)
TPAS, 8 mg kg ⁻¹	0.38	71 (7)	4.3 ± 2.3	100	18.5 (7)
TPFB, 6 mg kg ⁻¹	0.36	67 (10)	4.2 ± 1.9	111	18.9 (7)
TBDFD, 5 mg kg ⁻¹	0.02	87 (3)	3.1 ± 0.8	111	7.9 (7)
DBDHB, 6 mg kg ⁻¹	1.18	43 (3)	5.9 ± 1.5	111	18.7 (4)
Cisplatin, 5.5 mg kg ⁻¹	0.18	73 (3)	5.3 ± 1.3		0.9 (1)
Cisplatin, 9 mg kg ⁻¹	0.66	39 (7)	5.8 ± 1.6		8.8 (7)

GDF: growth delay factor; indicates the tumour doubling time gained by treatment. $GDF = (TD_{treated} - TD_{control}) / TD_{control}$.

T/C: (relative tumour volume of treated mice)/(relative tumour volume of control mice) × 100%.

TD: tumour doubling time.

ILS: increase in life span = $(MLS_{treated\ mice}) / (MLS_{untreated\ mice}) \times 100\%$. MLS: median life span.

MWL: maximum weight loss compared with the weight at first day of treatment ($d=0$).

References

- [1] (a) M. Bouâlam, M. Gielen, A. Meriem, D. de Vos and R. Willem, Anti-tumour compositions and compounds, Eur. Patent 90202316.7-, 1990; (b) M. Bouâlam, M. Gielen, A. El Khoulfi, D. de Vos and R. Willem, Novel organo-tin compounds having anti-tumour activity and anti-tumour compositions, Eur. Patent 91202746.3-, 1991.
- [2] M. Gielen, M. Bouâlam, A. Meriem, B. Mahieu, M. Biesemans and R. Willem, *Heteroat. Chem.*, 3 (1992) 449.
- [3] (a) M. Gielen, P. Lelieveld, D. de Vos and R. Willem, *In vitro* antitumour activity of organotin compounds, in M. Gielen (ed.), *Metal-Based Antitumour Drugs*, Vol. 2, Freund, Tel Aviv, 1992, pp. 29–54; (b) M. Gielen, P. Lelieveld, D. de Vos and R. Willem, *In vitro* antitumour activity of organotin(IV) derivatives of salicylic acid and related compounds, in B. Keppler (ed.), *Metal Complexes in Cancer Chemotherapy*, VCH, Weinheim, 1993, pp. 383–390; (c) M. Gielen, *Main Group Met. Chem.*, 17 (1994) 1; (d) M. Gielen and R. Willem, *Anticancer Res.*, 12 (1992) 257; (e) M. Gielen and R. Willem, *Anticancer Res.*, 12 (1992) 269; (f) M. Gielen and R. Willem, *Anticancer Res.*, 12 (1992) 1323.
- [4] M. Gielen, E. Joosen, T. Mancilla, K. Jurkschat, R. Willem, C. Roobol, J. Bernheim, G. Atassi, F. Huber, E. Hoffmann, H. Preut and B. Mahieu, *Main Group Met. Chem.*, 10 (1987) 147.
- [5] (a) M. Gielen, E. Joosen, T. Mancilla, K. Jurkschat, R. Willem, C. Roobol and J. Bernheim, Synthesis and *in vitro* antineoplastic activity of diorganostannylene derivatives of 2,6-pyridine dicarboxylic acid, in M. Nicolini (ed.), *Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy*, Martinus Nijhoff, Dordrecht, 1988, pp. 662–665; (b) R. Willem, M. Biesemans, M. Bouâlam, A. Delmotte, A. El Khoulfi and M. Gielen, *Appl. Organomet. Chem.*, 7 (1993) 311.
- [6] A.J. Crowe, The antitumour activity of tin compounds, in M. Gielen (ed.), *Metal-based Antitumour Drugs*, Vol. 1, Freund, Tel Aviv, 1989, pp. 103–149.
- [7] M. Gielen, M. Acheddad, B. Mahieu and R. Willem, *Main Group Met. Chem.*, 14 (1991) 73.

- [8] (a) M. Gielen, M. Acheddad and E.R.T. Tiekink, *Main Group Met. Chem.*, 16 (1993) 367; (b) M. Gielen, J. Meunier-Piret, M. Biesemans, R. Willem and A. El Khouloufi, *Appl. Organomet. Chem.*, 6 (1992) 59.
- [9] M. Gielen, M. Bouâlam, B. Mahieu and E.R.T. Tiekink, *Appl. Organomet. Chem.*, 8 (1994) 19.
- [10] (a) M. Gielen, A. El Khouloufi, M. Biesemans and R. Willem, *Appl. Organomet. Chem.*, 7 (1992) 119; (b) M. Gielen, A. El Khouloufi, M. Biesemans, F. Kayser and R. Willem, *Appl. Organomet. Chem.*, 7 (1993) 201.
- [11] M. Gielen, M. Biesemans, A. El Khouloufi, J. Meunier-Piret, F. Kayser and R. Willem, *J. Fluorine Chem.*, 64 (1993) 279.
- [12] M. Gielen, A. El Khouloufi, D. de Vos, H.J. Koiker, J.H.M. Schellens and R. Willem, *Bull. Soc. Chim. Belg.*, 102 (1993) 761.
- [13] M. Gielen, E.R.T. Tiekink, A. Bouhdid, D. de Vos, M. Biesemans, I. Verbruggen and R. Willem, *Appl. Organomet. Chem.*, 9 (1995) 639.
- [14] M. Gielen, R. Willem, M. Biesemans, M. Bouâlam, A. El Khouloufi and D. de Vos, *Appl. Organomet. Chem.*, 6 (1992) 287.
- [15] M. Gielen, A. El Khouloufi, M. Biesemans, A. Bouhdid, D. de Vos, B. Mahieu and R. Willem, *Met.-Based Drugs*, 1 (1994) 305.
- [16] M. Gielen, A. El Khouloufi, M. Biesemans, F. Kayser, R. Willem, B. Mahieu, D. Maes, J.N. Lisgarten, L. Wyns, A. Moreira, T.K. Chattopadhyay and R.A. Palmer, *Organometallics*, 13 (1994) 2849.
- [17] M. Gielen, R. Willem, A. Bouhdid, D. de Vos, C.M. Kuiper, G. Veerman and G.J. Peters, *In Vivo*, 9 (1995) 59.
- [18] (a) M. Gielen, P. Lelieveld, D. de Vos, H. Pan, R. Willem, M. Biesemans and H.H. Fiebig, *Inorg. Chim. Acta*, 196 (1992) 115; (b) M. Gielen, J. Meunier-Piret, M. Biesemans, A. El Khouloufi and R. Willem, *Polyhedron*, 11 (1992) 1861; (c) F. Kayser, M. Biesemans, M. Bouâlam, E.R.T. Tiekink, A. El Khouloufi, J. Meunier-Piret, A. Bouhdid, K. Jurkschat, M. Gielen and R. Willem, *Organometallics*, 13 (1994) 1098; (d) F. Kayser, M. Biesemans, M. Gielen and R. Willem, *Magn. Reson. Chem.*, 32 (1994) 358; F. Kayser, M. Biesemans, M. Gielen and R. Willem, *Main Group Met. Chem.*, 17 (1994) 559; (e) R. Willem, M. Biesemans, F. Kayser, M. Bouâlam and M. Gielen, *Inorg. Chim. Acta*, 197 (1992) 25; (f) R. Willem, M. Biesemans, F. Kayser, M. Bouâlam and M. Gielen, *Inorg. Chim. Acta*, 197 (1992) 25.